Background
Align Technology is the company behind Invisalign, the world’s dominant clear dental aligner system with more than 16 million patients treated globally. ClearCorrect, a Straumann Group subsidiary, is one of Invisalign’s most direct competitors in the direct-to-consumer and orthodontic-practice aligner market. In 2024, Align sued ClearCorrect in the Western District of Texas, asserting four patents directed to multilayer dental aligner materials and polymer sheet technology:
- U.S. Patent No. 10,973,613 — Multilayer dental appliances
- U.S. Patent No. 11,154,384 — Multilayer dental appliances
- U.S. Patent No. 11,648,090 — Multilayer polymer sheets
- U.S. Patent No. 11,648,091 — Multilayer polymer sheets
ClearCorrect mounted a vigorous defence, asserting both invalidity of the patents and antitrust counterclaims—arguing that Align had illegally leveraged its market dominance to suppress competition in the clear aligner market.
The Court’s Holding
The jury delivered a split verdict. On infringement: all four of Align’s asserted patents were found infringed by ClearCorrect’s products. On validity: all four patents were found invalid—meaning the jury agreed with ClearCorrect’s invalidity defences, likely based on anticipation or obviousness over prior art. Because invalidity negates the ability to enforce an infringed patent, the verdict means Align cannot use these four patents to block ClearCorrect or collect damages, despite the infringement finding.
The jury also rejected ClearCorrect’s antitrust, false advertising, and unfair competition counterclaims in their entirety. So while Align lost the patents it was asserting, ClearCorrect did not obtain any affirmative antitrust relief.
Key Takeaways
- A finding of infringement without valid patents is a complete loss for the patent holder: Align’s four asserted patents are no longer enforceable against ClearCorrect or anyone else following the invalidity verdict.
- Invalidity findings in jury trials require proof by clear and convincing evidence—that the jury reached this conclusion on all four patents signals significant prior art or other invalidity grounds were presented.
- ClearCorrect’s failed antitrust counterclaims illustrate how difficult it is to turn a patent dispute into an antitrust victory: courts and juries are skeptical of “sham litigation” and monopolisation theories in patent enforcement contexts.
- Align retains a large portfolio of other patents covering different aspects of its Invisalign system; this verdict narrows but does not eliminate its IP protection in the aligner market.
Why It Matters
The clear aligner market is one of the fastest-growing segments of dentistry and orthodontics, and Align Technology has used its extensive patent portfolio as a strategic moat against competitors. This verdict represents a significant crack in that wall—four patents covering core multilayer aligner material technology are now invalid and unenforceable. For ClearCorrect and other aligner manufacturers (including numerous startups and international entrants), the ruling opens a path to competing on those specific material technologies without infringing a valid Align patent.
Post-verdict, both parties have legal options. Align can move for judgment as a matter of law (JMOL) challenging the invalidity finding, or appeal to the Federal Circuit. If the invalidity finding stands, it becomes prior art—potentially affecting Align’s ability to assert related patents as well. This case is one to watch closely as the clear aligner IP wars continue.
Surfaced via Law360 IP.